Dose-ranging kinetics and behavioral pharmacology of naltrexone and acamprosate, both alone and combined, in alcohol-dependent subjects

Journal of Clinical Psychopharmacology

Volumn 23, Issue 3, 2003, Pages 281-293

  Johnson, Bankole A ^a,b   O'Malley, Stephanie S ^c   Ciraulo, Domenic A ^d   Roache, John D ^a,b   Chambers, Robert A ^c   Sarid Segal, Ofra ^d   Couper, David ^e  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b Mays Cancer Center at UT Health San Antonio   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e IL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACAMPROSATE; ACETYLHOMOTAURINE; DRUG METABOLITE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NALTREXOL; NALTREXONE; OPIATE ANTAGONIST; PLACEBO; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; ALCOHOLISM; ANGER; ARTICLE; BEHAVIOR; BLOOD CELL COUNT; BLOOD CHEMISTRY; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEPRESSION; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG MEGADOSE; DRUG SAFETY; DYSPHAGIA; FATIGUE; FEMALE; HEADACHE; HUMAN; LOW DRUG DOSE; MALE; MONOTHERAPY; MOOD; NERVOUSNESS; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; RANDOMIZED CONTROLLED TRIAL; SLEEP; SOMNOLENCE; STOMACH EMPTYING; VOMITING;

EID: 0038341150     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jcp.0000084029.22282.bb     Document Type: Article

References (47)

1. Johnson BA, Ait-Daoud N. Neuropharmacological treatments for alcoholism: scientific basis and clinical findings. Psychopharmacology (Berl). 2000;149:327-344.
2. Koob GF. Drugs of abuse: anatomy, pharmacology and function of reward pathways. Trends Pharmacol Sci. 1992;13:177-184.
3. Hemby SE, Johnson BA, Dworkin SI. Neurobiological basis of drug reinforcement. In: Johnson BA, Roache JD, eds. Drug Addiction and Its Treatment: Nexus of Neuroscience and Behavior. Philadelphia: Lippincott-Raven, 1997:137-169.
4. Volpicelli JR, Alterman AI, Hayashida M, et al. Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry. 1992;49:876-880.
5. O'Malley SS, Jaffe AJ, Chang G, et al. Naltrexone and coping skills therapy for alcohol dependence: a controlled study. Arch Gen Psychiatry. 1992;49:881-887.
6. Spanagel R, Zieglgansberger W. Anti-craving compounds for ethanol: new pharmacological tools to study addictive processes. Trends Pharmacol Sci. 1997;18:54-59.
7. Mason B. Acamprosate treatment of alcohol dependence: results of the US multicenter study. Presented at the meeting of the Society of Biological Psychiatry (New Orleans, LA), 2001.
8. Mason BJ, Goodman AM, Dixon RM, et al. A pharmacokinetic and pharmacodynamic drug interaction study of acamprosate and naltrexone. Neuropsychopharmacology. 2002;27:595-606.
9. Sullivan JT, Sykora K, Schneiderman J, et al. Assessment of alcohol withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar). Br J Addict. 1989;84:1353-1357.
10. Haertzen CA, Hill HE, Belleville RE. Development of the addiction research center inventory (ARCI): selection of items that are sensitive to the effects of various drugs. Psychopharmacologia. 1963;4:155-166.
11. Roache JD, Griffiths RR. Diazepam and triazolam self-administration in sedative abusers: concordance of subject ratings, performance and drug self-administration. Psychopharmacology (Berl). 1989;99:309-315.
12. Foltin RW, Fischman MW. Smoked and intravenous cocaine in humans: acute tolerance, cardiovascular and subjective effects. J Pharmacol Exp Ther. 1991;257:247-261.
13. Higgins ST, Bickel WK, Hughes JR, et al. Effects of intranasal cocaine on human learning, performance and physiology. Psychopharmacology (Berl). 1990;102:451-458.
14. Johnson BA, Oldman D, Goodall EM, et al. Effects of GR 68755 on d-amphetamine-induced changes in mood, cognitive performance, appetite, food preference, and caloric and macronutrient intake in humans. Behav Pharmacol. 1996;7:216-227.
15. Roache JD, Thomson W, Schmitz J, et al. Methylphenidate effects in cocaine dependent patients: laboratory assessment and treatment outcome. In: Harris LS, ed. College on Problems of Drug Dependence 1994: Proceedings of the 56th Annual Scientific Meeting. 1995:218.
16. McNair DM, Lorr M, Droppleman LF. Manual of the Profile of Mood States. San Diego, CA: Educational and Industrial Testing Service, 1971.
17. Buysse DJ, Reynolds CF, Monk TH, et al. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989;28:193-213.
18. Johnson B, Overton D, Wells L, et al. Effects of acute intravenous cocaine on cardiovascular function, human learning, and performance in cocaine addicts. Psychiatry Res. 1998;77:35-42.
19. Silverstone PH, Oldman D,Johnson B, et al. Ondansetron, a 5-HT3 receptor antagonist, partially attenuates the effects of amphetamine: a pilot study in healthy volunteers. Int Clin Psychopharmacol. 1992;7:37-43.
20. McLeod DR, Griffiths RR, Bigelow GE, et al. An automated version of the digit symbol substitution test (DSST). Behav Res Methods Instrum Comput. 1982;14:463-466.
21. Brandt J. The Hopkins Verbal Learning Test: development of a new memory test with six equivalent forms. Clin Neuropsychol. 1991;5:125-142.
22. Doolan PD, Alpen EL, Theil GB. A clinical appraisal of the plasma concentration and endogenous clearance of creatinine. Am J Med. 1962;32:65.
23. Bennett WM, Porter GA. Endogenous creatinine clearance as a clinical measure of glomerular filtration rate. Br Med J. 1971;4:84-86.
24. Tobias GJ, McLaughlin RJ, Hopper JJ. Endogenous creatinine clearance: a valuable clinical test of glomerular filtration and prognostic guide in chronic renal disease. N Engl J Med. 1962;266:317.
25. Miller TR, Anderson RJ, Linas SL, et al. Urinary diagnostic indices in acute renal failure: a prospective study. Ann Intern Med. 1978;89:47-50.
26. Espinel CH, Gregory AW. Differential diagnosis of acute renal failure. Clin Nephrol. 1980;13:73-77.
27. Lameire NH, Lifschitz MD, Stein JH. Heterogeneity of nephron function. Annu Rev Physiol. 1977;39:159-184.
28. Goldstein RS. Biochemical heterogeneity and site-specific tubular injury. In: Hook JB, Goldstein RS, eds. Toxicology of the Kidney. New York: Raven Press, 1993:201-245.
29. Tyson CA, Story DL, Green CE, et al. Traditionally used indicators in relation to pathologic lesions. In: Tyson CA, Sawhney DS, eds. Organ Function Tests in Toxicity Evaluation. Park Ridge: Noyes Publications, 1985:23-89.
30. Gunder WG, Ross BR. Enzyme distribution along the nephron. Kidney Int. 1984;26:101-111.
31. Harvey JN, Edmundson AW, Jaffa AA, et al. Renal excretion of kallikrein and eicosanoids in patients with type 1 (insulin-dependent) diabetes mellitus: relationship to glomerular and tubular function. Diabetologia. 1992;35:857-862.
32. Foulkes EC. Functional assessment of the kidney. In: Hook JB, Goldstein RS, eds. Toxicology of the Kidney. New York: Raven Press; 1993:37-60.
33. Mitoma C. Tests for renal function. In: Tyson CA, Sawhney DS, eds. Organ Function Tests in Toxicity Evaluation. Park Ridge: Noyes Publications, 1985:109-122.
34. Schiffer R, Klein R, Sider R. The Medical Evaluation of Psychiatric Patients. New York: Plenum Medical Book Company, 1988.
35. Mueller J, Fogel B. Neuropsychiatry. Baltimore: Williams & Wilkins, 1996.
36. Brey RL, Thornton JE, Johnson BA. Systematic and Quantified Neurological Evaluation. San Antonio: University of Texas Departments of Neurology, Psychiatry, and Pharmacology; 1998 (Courtesy of the Southwest Texas Addiction Research and Technology [START] Center).
37. Kosten TR, Rounsaville BJ, Kleber HD. Comparison of clinician ratings to self reports of withdrawal during clonidine detoxification of opiate addicts. Am J Drug Alcohol Abuse. 1985;11:1-10.
38. Levine J, Schooler NR. SAFTEE: a technique for the systematic assessment of side effects in clinical trials. Psychopharmacol Bull. 1986;22:343-381.
39. Johnson BA, Thornton JE, Brey RL. Systematic Conduct of the SAFTEE Interview. San Antonio: University of Texas Departments of Neurology, Psychiatry, and Pharmacology, 1998 (Courtesy of the Southwest Texas Addiction Research and Technology [START] Center).
40. Verebey K, Volavka J, Mule SJ, et al. Naltrexone: disposition, metabolism, and effects after acute and chronic dosing. Clin Pharmacol Ther. 1976;20:315-328.
41. SAS Institute, Inc. SAS User's Guide: Statistics, Version 6.12. 6th ed. Cary, NC: SAS Institute, Inc.; 1997.
42. Saivin S, Hulot T, Chabac S, et al. Clinical pharmacokinetics of acamprosate. Clin Pharmacokinet. 1998;35:331-345.
43. Kapusta DR, Obih JC, Dibona GF. Central mu opioid receptor-mediated changes in renal function in conscious rats. J Pharmacol Exp Ther. 1993;265:134-143.
44. Kapusta DR, Jones SY, DiBona GF. Renal mu opioid receptor mechanisms in regulation of renal function in rats. J Pharmacol Exp Ther. 1991;258:111-117.
45. Helm JF, Venu RP, Geenen JE, et al. Effects of morphine on the human sphincter of Oddi. Gut. 1988;29:1402-1407.
46. Bird KJ. Narcotic-induced choledochoduodenal sphincter spasm reversed by naloxone: a case report and review. Anaesthesia. 1986;41:1120-1123.
47. Asai T, Power I. Naloxone inhibits gastric emptying in the rat. Anesth Analg. 1999;88:204-208.